IRIS
MINETTO, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.508
AS - Asia 64
SA - Sud America 16
NA - Nord America 2
AF - Africa 1
Totale 3.591
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 3.508
CN - Cina 48
BR - Brasile 14
VN - Vietnam 9
SG - Singapore 6
US - Stati Uniti d'America 2
AR - Argentina 1
BD - Bangladesh 1
EC - Ecuador 1
TN - Tunisia 1
Totale 3.591
Salva come PNG Salva come JPEG
Città #
Genova 1.525
Genoa 1.319
Rapallo 368
Vado Ligure 283
Beijing 22
Bordighera 9
Hanoi 4
Ho Chi Minh City 3
Perugia 3
Singapore 3
Araruama 1
Ashburn 1
Campina Grande do Sul 1
Chapada Gaúcha 1
Curitiba 1
Da Nang 1
Dois Vizinhos 1
Guarulhos 1
Hortolândia 1
Itu 1
Joinville 1
Lorena 1
Macapá 1
Manta 1
Menzel Temime 1
Milltown 1
Morón 1
Pouso Alegre 1
Quảng Ngãi 1
Sátiro Dias 1
Vitória 1
Totale 3.560
Salva come PNG Salva come JPEG
Nome #
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 212
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis 182
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 179
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 178
Metabolic starvation triggered by l-asparaginase sensitizes multiple myeloma cells to proteasome inhibitors by inducing DNA damage accumulation 172
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes 168
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 164
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia 160
Feasibility and Efficacy of Post-Transplant Consolidation Immunotherapy with Nivolumab Supported By the Reinfusion of Unselected Autologous Lymphocytes in Patients Affected By Relapsed/Refractory Hodgkin Lymphoma 160
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 155
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives 154
Harnessing NK Cells for Cancer Treatment 150
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 147
Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies 146
Chronic graft versus host disease as a weapon for treating chronic myelomonocytic leukemia 143
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 140
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 139
Adoptive Cell Therapy and Immune Check Points Inhibitors As a Salvage Treatment for Patient Affected By Relapsed/Refractory Hodgkin's Lymphoma 138
Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas 122
Cancer immunotherapy by blocking immune checkpoints on innate lymphocytes 120
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 107
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 106
A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML 88
Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation 61
Good tolerability of high dose colistin-based therapy in patients with haematological malignancies 56
Long-term real world evidence of CPX-351 of high-risk AML patients identified high rate of negative MRD and prolonged OS 50
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 34
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study 32
Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group 20
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience 11
Totale 3.694
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.935
article - articoli 12.454
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.389
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021272 0 0 0 0 39 52 6 38 22 46 21 48
2021/2022311 4 8 22 44 28 28 13 56 26 27 18 37
2022/2023443 38 47 7 41 82 54 2 25 56 28 55 8
2023/2024345 9 27 6 36 22 80 37 74 8 10 18 18
2024/2025835 14 42 21 58 76 99 100 177 23 38 85 102
2025/2026458 169 36 75 178 0 0 0 0 0 0 0 0
Totale 3.694